Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...

Tanzania President, Namibia President Elect and Merck Foundation Chief Executive Officer (CEO) named amongst 100 Most ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

Summit Therapeutics has soared due to hopes around its cancer drug candidate, ivonescimab. It outperformed Keytruda in a phase 3 trial for treating advanced non-small cell lung cancer. Investors ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Oosthuizen increased their investment in Merck & Co by purchasing 8,664 shares through ...

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Chirfi Guindo, Chief Marketing Officer at Merck & Co MRK.

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Ginkgo Bioworks faces ongoing revenue declines and high cash burn, despite cost-cutting efforts. Find out why I maintain a ...